Correspondence: Time to think differently? Spriggs to Friedlander

open access

Correspondence:

"In a recent letter, Friedlander et al1 discuss the role of symptom
benefit in platinum-resistant or -refractory ovarian cancer. Qualityof-
life (QoL) assessments are of extreme importance in this patient
population and particularly in this setting of platinum-resistant, recurrent ovarian cancer. For this reason, evaluation of patient-reported
symptoms and QoL by the Functional Assessment of Cancer Therapy-
Ovary (FACT-O) and FACT-O Symptom Index were secondary objectives
in the phase III study that compared patupilone with pegylated
liposomal doxorubicin in this patient population, and the results were
published online as supplementary material.2 ...........

REFERENCES

1. Friedlander ML, Stockler MR, Butow P, et al: Clinical trials of palliative chemotherapy in platinum-resistant or -refractory ovarian cancer: Time to think differently? J Clin Oncol doi: 10.1200/JCO.2012.47.7927

2. Spriggs DR: Drug development for chronic cancers: Time to think differently? J Clin Oncol 30:3779-3780, 2012

3. Colombo N, Kutarska E, Dimopoulos M, et al: Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. J Clin Oncol 30:3841-3847, 2012